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Abstract
Background: Well-differentiated neuroendocrine carcinomas are highly vascularized and may be
sensitive to drugs administered on a metronomic schedule that has shown antiangiogenic
properties. A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU)
infusion plus long-acting release (LAR) octreotide in patients with neuroendocrine carcinoma.
Methods: Twenty-nine patients with metastatic or locally advanced well-differentiated
neuroendocrine carcinoma were treated with protracted 5FU intravenous infusion (200 mg/m2
daily) plus LAR octreotide (20 mg monthly). Patients were followed for toxicity, objective
response, symptomatic and biochemical response, time to progression and survival.
Results: Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) criteria showed
partial response in 7 (24.1%), stable disease in 20 (69.0%), and disease progression in 2 patients.
Response did not significantly differ when patients were stratified by primary tumor site and
proliferative activity. A biochemical (chromogranin A) response was observed in 12/25 assessable
patients (48.0%); symptom relief was obtained in 9/15 symptomatic patients (60.0%). There was
non significant decrease in circulating vascular epithelial growth factor (VEGF) over time. Median
time to progression was 22.6 months (range, 2.7-68.5); median overall survival was not reached
yet. Toxicity was mild and manageable.
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BMC Cancer 2009, 9:388 http://www.biomedcentral.com/1471-2407/9/388Conclusion: Continuous/metronomic 5FU infusion plus LAR octreotide is well tolerated and
shows activity in patients with well-differentiated neuroendocrine carcinoma. The potential
synergism between metronomic chemotherapy and antiangiogenic drugs provides a rationale for
exploring this association in the future.
Trial registration: NCT00953394
Background
Well-differentiated neuroendocrine carcinomas are a
group of rare malignancies generally characterized by low
aggressiveness [1-4]. Surgery is the only curative modality.
In unresectable disease, somatostatin analogues effec-
tively reduce hormonal hypersecretion, but tumor shrink-
age is only rarely seen (0%-6% of patients) [5,6].
Because of their low proliferative activity, conventional
chemotherapy for these tumors is not recommended [7-
9]. Metronomic chemotherapy, i.e., the frequent adminis-
tration of cytotoxic drugs at low doses [10], has demon-
strated antiangiogenetic properties [11-13]. Since well-
differentiated neuroendocrine carcinomas are highly vas-
cular [14,15], there is a rationale for testing metronomic
chemotherapy in this clinical setting [16].
Five-fluorouracil (5FU) is frequently employed in the
treatment of advanced neuroendocrine carcinoma [17-
19]. The combination of protracted 5FU infusion and alfa
2b interferon has been tested in the treatment of well-dif-
ferentiated neuroendocrine carcinomas of the gastroen-
teropancreatic tract, and a disease response obtained in
more than 40% of patients [20]. Moreover, concomitant
administration of somatostatin analogues to enhance the
effect of the antiproliferative activity of 5FU has been
reported in several in vitro and in vivo preclinical studies
[21].
On these grounds, the Piemonte Region Oncology Net-
work conducted a multicenter phase II trial to assess the
activity and safety profile of a combination regimen of
protracted 5FU infusion and long-acting release (LAR)
octreotide in patients with advanced well-differentiated
neuroendocrine carcinomas. The primary study aim was
to assess response to treatment; the secondary aims were
to evaluate toxicity, biochemical and symptomatic
response, time to progression and survival.
Methods
Study population
Eligibility criteria included histological diagnosis of well-
differentiated neuroendocrine carcinoma according to the
World Health Organization (WHO) classification [1],
locally advanced or metastatic disease not amenable to
surgery with radical intent, at least one measurable target
lesion, radiological documentation of progressive disease,
somatostatin receptor scintigraphy, Eastern Cooperative
Oncology Group (ECOG) performance status grade ≤ 2,
life expectancy ≥ 12 weeks, adequate bone marrow reserve
(WBC count ≥ 3.5 × 109/L, platelets ≥ 100 × 109/L, hemo-
globin ≥ 10 g/dL), adequate hepatic and renal function
(hepatic enzymes and bilirubin < 2 × upper limit of nor-
mal, serum creatinine < 1.4 mg/dl). Exclusion criteria
were non-malignant systemic disease or conditions that
precluded patients from receiving the study therapy, sec-
ond primary malignancies, and previous systemic antine-
oplastic treatment including somatostatin analogues.
Diagnostic work-up included physical examination,
screening chemistry, circulating chromogranin A (CgA),
abdominal, chest and pelvis computed tomography (CT),
and somatostatin receptor scintigraphy. The study was
approved by the local ethic committee of each participat-
ing center. Written informed consent was obtained from
all patients before starting treatment.
Histology and immunohistochemical analysis
The histological diagnoses performed at each center were
centrally reviewed by two experienced pathologists using
the proposed morphological criteria for well-differenti-
ated neuroendocrine carcinoma [1]. In addition, immu-
nohistochemical analysis of the Ki-67 proliferation index
(DakoCytomation, Glostrup, Denmark, clone MIB-1,
diluted 1/300), type 2 somatostatin receptor expression
(BioTrend, Cologne, Germany, code SS-800, diluted 1/
3000) and VEGF marker levels (NeoMarkers, Fremont,
CA, USA, polyclonal, diluted 1/250) was performed.
Treatment plan and toxicity assessment
LAR octreotide acetate at a dose of 20 mg was adminis-
tered intramuscularly every 4 weeks. The first administra-
tion was matched to an induction treatment of octreotide
(0.1 mg subcutaneous every 8 h) for 14 days; 5FU was
given as a protracted continuous infusion without inter-
ruption at a daily dose of 200 mg/m2 of body-surface area
through an elastomeric pump connected to a central
venous access.
5FU treatment was planned to be administered for 6
months, however, prolonged 5FU administration beyond
6 months was permitted. LAR octreotide administration
was continued until disease progression.Page 2 of 8
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tute Common Toxicity Criteria (NCI CTC) [22].
5FU dose modifications were performed as follows: if
WBC count was < 2500/mL and/or platelet count <
100,000/mL, 5FU was delayed for 1 week. If the blood
count did not recover, then 5FU was delayed for a further
week and the dose reduced by 25%. In the event of severe
plantar-palmar erythema with blistering and desquama-
tion, 5FU was interrupted until healing had occurred. In
the event of persistent diarrhea and/or grade 2 mucositis,
5FU was discontinued for 1 week. If grade 3/4 diarrhea
and mucositis occurred, 5FU was withdrawn until recov-
ery then resumed at a dose reduced by 25%.
Response evaluation
A CT scan was performed every 12 weeks after initiation of
treatment. Disease response was evaluated according to
RECIST criteria [23].
Symptomatic patients were asked to keep a diary where
they reported frequency and duration of disease-related
symptoms. CR was defined as the complete relief of all
symptoms and PR as a reduction of at least 50% in both
the frequency and intensity of symptoms.
Circulating CgA was measured every 3 months using a
commercially available assay (DAKO ELISA, DAKO A/S,
Glostrup, Denmark). A decline in CgA levels was consid-
ered a biochemical response and defined as either a CR if
the tumor marker level returned to normal or as a PR if
tumor marker levels decreased by 50% or more. An
increase of more than 25% in CgA levels was defined as
biochemical progression.
Circulating VEGF levels were retrospectively assessed
using a sandwich enzyme immunoassay technique with a
monoclonal antibody specific for VEGF (R&D System
Europe, Abingdon, UK) in plasma samples collected at
baseline and after 3 and 6 months in 11 patients, all
recruited at the study coordinating center (San Luigi Hos-
pital, Orbassano, Torino).
Statistical analysis
The primary end point of the study was the response rate.
A Simon two-stage design [24] was used to test the null
hypothesis that the true objective response rate was <
10%. The upper limit of first-step drug rejection was 1
response (CR or PR) in the first 10 consecutive patients;
the upper limit of second-step rejection was 5 responses in
29 consecutively enrolled patients. Time to progression
(TTP) and overall survival (OS) were assessed using the
Kaplan-Meier product limit estimate method. The rates of
TTP and OS were measured from the date of treatment
start to the date of progression and the date of last follow-
up or death, respectively. A Cox proportional-hazards
regression analysis was used to assess in multivariate anal-
ysis the prognostic role of mitosis count and Ki67 expres-
sion. Changes in VEGF levels over time were assessed by
the Friedman analysis of variance for non parametric
matched paired data. P values < 0.05 were considered sta-
tistically significant. Statistical analyses were performed
using the Statistica/PC software program (Statsoft, Tulsa
OK, USA).
Results
Patient characteristics
Twenty-nine patients with locally advanced or metastatic
disease with radiological documentation of progressive
disease were entered into the study at the seven participat-
ing centers from 2004 to 2006. The baseline patient char-
acteristics are depicted in Table 1. No patients had
received any previous systemic antineoplastic treatment
including somatostatin analogues. None had received
radionuclide therapy before entry into the study.
A diagnosis of well-differentiated neuroendocrine carci-
noma was confirmed in 28 patients by central histological
review. One patient had a poorly differentiated carcinoma
and was therefore ineligible. However, according to the
intent-to-treat principle, this patient was included in the
analyses.
Treatment and toxicity
5FU treatment was administered for a median duration of
6 months (range, 2-9). Twenty-three patients (79.3%)
completed the scheduled 6-month 5FU treatment. Six
patients interrupted earlier because of disease progression
(2 cases), patient decision (1 case), radionuclide therapy
(2 cases), and surgical debulking to control an insulinoma
syndrome (1 case). Associated side effects were mild
(Table 2). No hematologic grade III-IV events were
recorded. Grade II-III mucositis and diarrhea occurred in
3 patients (10.3%). Two patients (6.9%) developed grade
III hand-foot syndrome. 5FU administration was delayed
for at least 1 week in 8 patients (27.6%) and for 2 weeks
in 3 patients (10.3%). The reasons for the delayed course
were hematological in 1 patient and non-hematological
(mucositis, diarrhea, cutaneous) in the other 10 cases.
5FU infusion was reduced by 75% in 2 patients due to old
age and grade III diarrhea and reduced by 50% in 1
patient due to grade III mucositis.
Treatment activity
Seven patients attained a PR (24.1%), 20 SD (69.0%), and
2 (6.9%) progressed (Table 3). Disease responses were
observed in patients with liver (5 patients) and lymph
node metastasis (2 patients).Page 3 of 8
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Table 1: Patient characteristics
Patients N = 29
Median age (range) - yrs 59 (26 -- 80)
Gender -- no. (%)
Male (%) 15 (52.0)
Female (%) 14 (48.0)
ECOG performance status -- no. (%)
0 11 (37.9)
1 17 (58.6)
2 1 (3.5)
Primary tumor site -- no. (%)
Pancreas 13 (44.8)
Functioning 5 (17.2)
Unknown 7 (24.2)
Small bowel 7 (24.2)
Appendix 1 (3.4)
Colon 1 (3.4)
Tumor Stage -- no. (%)
Locally advanced/metastatic 2/27
Site of metastases -- no. (%)
< 2 sites 13 (44.8)
≥ 2 sites 16 (55.2)
Prior therapies -- no. (%)
Surgery 9 (31.0)
Progressive disease 29 (100)
Baseline symptoms -- no. (%)
Diarrhea 6 (20.6)
Flushing 4 (13.8)
Carcinoid syndrome 4 (13.8)
Hypoglycemia 2 (6.9)
Others 10 (34.5)
Circulating chromogranin A levels (U/L) - no. (%)
Normal levels 4 (13.8)
Supranormal levels 25 (86.2)
Histological tumor characteristics -- no. (%)
SST2
1+ 2 (9.1)
2+ 8 (36.4)
3+ 12 (54.5)
missing 7
Mitosis (per square millimeter)
< 2 17 (68.0)
2 -- 20 7 (28.0)
> 20 1 (4.0)
missing 4
Ki67
≤ 2% 11 (42.3)
3 -- 10% 13 (50.0)
> 10% 2 (7.7)
missing 3
VEGF
0 3 (15.8)
1 4 (21.1)
2 7 (36.8)
3 5 (26.8)
missing 10
SST2 = somatostatin receptor type 2
VEGF = vascular endothelial growth factor
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48% and 60% of patients, respectively. After medical
treatment, surgery was carried out in 3 patients: 1 with a
PR and 2 with SD (minimal tumor shrinkage < 20%). One
patient was operated for surgical removal of a primary
pancreatic tumor and chemoembolization of liver metas-
tases; 1 patient underwent right hemicolectomy plus
intraoperative radiofrequency ablation of liver metastases,
1 patient underwent radical excision of a primary pancre-
atic tumor and liver metastases. Disease response did not
change when the patients were stratified by primary dis-
ease site, mitotic count and Ki67.
In the 11 patients with circulating VEGF assessed before
and after treatment, there was a non significant trend of
progressive marker reduction over time (mean VEGF lev-
els 147, 96, and 67 pg/ml at baseline, 3 and 6 months,
respectively, P = 0.33). VEGF decreased > 50% from base-
line in 5 patients, between 25 and 50% in 2, < 25% in 2,
and increased > 25% in 2.
Predictors of patient outcome
At the last follow-up evaluation, 16 (55.2%) patients
showed disease progression and 7 (24.1%) had died; the
median duration of follow-up was 51 months.
The median TTP of all 29 patients was 22.6 months
(range, 2.7-68.5), while the median OS was not reached.
After 2 years, 48% of patients were free from progression
and 82% were alive. In the univariate analysis, Ki67
immunostaining at a cutoff value ≤ 2% and mitotic count
at a cutoff value < 2% were predictors of either TTP (P <
0.005 and P < 0.003) or OS (P = 0.06 and P = 0.004) (Fig-
ure 1), while age, sex, patient performance status, primary
disease site and VEGF expression were not. In the multi-
variate analysis, Ki67 (continuous variable) but not
mitotic count was an independent predictor of either dis-
ease recurrence (hazard ratio [HR] 1.03, 95% confidence
interval [CI] 1.00-1.06; P = 0.05) or death (HR 1.04, 95%
CI 1.00-1.08; P < 0.04). Of the 3 patients who underwent
surgery after treatment, only 1 patient progressed after
20.0 months. The remaining 2 patients were alive and free
from progression after 29.7 and 35.1 months, respec-
tively.
Discussion
In this multicenter phase II trial, protracted 5-fluorouracil
(5FU) infusion administered in combination with LAR
octreotide was an active regimen in the upfront treatment
of advanced neuroendocrine carcinomas. This regimen
was associated with an overall objective response rate of
24%, a biochemical response rate of 48%, and a sympto-
matic response rate of 60%. To our knowledge, this is the
first trial to test the activity of the combination of octre-
otide and a chemotherapy drug in somatostatin-naïve
patients. Due to the rarity of neuroendocrine tumors, this
trial was not randomized and this represents a limitation.
Nonetheless, the objective response rate obtained here
seems to be higher than that expected with somatostatin
alone (0-6%) [4,8,25]. The recently presented results of
the first randomized study testing the efficacy of octre-
otide versus placebo in metastatic well-differentiated neu-
roendocrine carcinoma showed that octreotide was
superior to placebo in prolonging time to progression,
despite a comparable response rate [26]. These data fur-
ther confirm that the antineoplastic activity of somatasta-
tin analogues is not due to tumor shrinkage but rather to
Table 2: Treatment-related toxicity.
Higher grade WHO toxicity N = 29
No. (%)
N = 29
No. (%)
N = 29
No. (%)
1 2 3
Anemia -- 2 (6.9) --
Thrombocytopenia 1 (3.4) -- --
Neutropenia 2 (6.9) 2 (6.9) --
Asthenia 9 (31.0) 2 (6.9) --
Nausea-vomiting 7 (24.1) 1 (3.4) --
Diarrhea 16 (55.1) 2 (6.9) 1(3.4)
Hand-foot syndrome 4 (13.8) 4 (13.8) 2 (6.9)
Mucositis 4 (13.8) 2 (6.9) 1 (3.4)
Table 3: Response to treatment
Clinical response
(RECIST)
N = 29
No. (%)
Biochemical response (Chromogranin A)
N = 25
No. (%)
Symptomatic response
N = 15
No. (%)
Progression 2 (6.9) 2 (8.0)
No change 20 (69.0) 11 (44.0) 6 (40.0)
Partial response 7 (24.1) 8 (32.0) 6 (40.0)
Complete response - 4 (16.0) 3 (20.0)
Overall response 7 (24.1)
(95% CI 8.3-39.9)
12 (48.0)
(95% CI 28.0-68.0)
9 (60.0)
RECIST = Response Evaluation Criteria in Solid TumorsPage 5 of 8
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BMC Cancer 2009, 9:388 http://www.biomedcentral.com/1471-2407/9/388a prolonging of disease stabilization. The potentiality of
continuous 5FU in inducing tumor shrinkage could
improve the efficacy of systemic treatment, a finding that
needs to be assessed in a randomized study.
Due to the potential dedifferentiation of neuroendocrine
carcinomas as a consequence of progression, it is expected
that response to treatment in metastatic sites may differ
from that of primary lesions. Our series was homogene-
ous in this respect, since 27 out of 29 patients had meta-
static disease. Tumor shrinkage (partial response or
minimal response) obtained by our regimen made sur-
gery for residual disease (with/without liver chemoembol-
ization or liver radiofrequency ablation) feasible in 3
patients. Surgery for residual disease seemed to be effica-
cious, since 2 patients were disease free at the last follow-
up examination after 27 and 35 months, respectively.
In order to verify study population homogeneity, the
tumor samples were centrally reviewed by two patholo-
gists. Central review also allowed the pathologists to
assess the biological prognostic parameters. Significant
outcome predictors were mitotic count and Ki67 prolifer-
ation index, both parameters being reciprocally corre-
lated. Only Ki67, however, maintained an independent
prognostic role in the multivariate analysis, confirming
the importance of assessing this marker in these tumors
[27,28]. Ki67 is also an essential parameter in the pro-
posed grading system for foregut neuroendocrine tumors
of the stomach, duodenum, and pancreas [29]. The pro-
posed cutoff of 2% to discriminate G1 from G2 carcino-
mas was associated with better outcome, confirming a
recent report [30]. Ki67 is also used as predictive marker
of treatment response in clinical decision-making algo-
rithms [7,31]. It has been suggested that neuroendocrine
Time to progression (1a and 1b) and overall survival (1c and 1d) according to Ki67 expression at the cutoff of 2% positive cells and mitosis countF gure 1
Time to progression (1a and 1b) and overall survival (1c and 1d) according to Ki67 expression at the cutoff of 
2% positive cells and mitosis count.
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sensitive to conventional chemotherapy, whereas tumors
with lower Ki67 expression may not [31]. This trend was
confirmed in our series but failed to attain statistical sig-
nificance.
It has been suggested that metronomic chemotherapy has
antiangiogenetic activity [10]. The activity of metronomic
chemotherapy in reducing circulating VEGF levels was
observed in a previous study in patients with advanced
breast cancer [32]. In the present study, plasma VEGF lev-
els monitored every 3 months in 11 patients showed a
stepwise reduction over time that failed to attain statistical
significance due to the small sample size. On an individ-
ual basis, however, 7 patients were noted to have a
decrease in VEGF and only 2 an increase. Taken together,
these data evince an antiangiogenic effect of continuous
5FU plus octreotide treatment.
In a recent Italian multicenter study, a combination of
oxaliplatin and metronomic capecitabine (an oral 5FU
analogue) was administered to 40 patients with malig-
nant neuroendocrine tumors. Interestingly, a disease
response was observed in 23% of patients with high-grade
and in 30% of those with low-grade neuroendocrine
tumors, respectively [33]. The introduction of metro-
nomic capecitabine could account for the high response
rate obtained in this well-differentiated subset.
Continuous 5FU infusion in this patient subset was well
tolerated as most toxicities observed were mild (grade I or
II). As expected, dose-limiting toxicities were non hema-
tolological (mucositis, diarrhea, hand-foot syndrome)
and delayed treatment in 40% of patients.
Conclusion
The combination of 5FU continuous infusion and LAR
octreotide is an active regimen in the treatment of meta-
static well-differentiated neuroendocrine carcinomas and
may have antiangiogenic activity. The potential synergism
between metronomic chemotherapy and antiangiogenic
drugs provides a rationale for exploring this association in
the future. Moreover, capecitabine is an orally available
5FU derivative found to have the same efficacy as contin-
uous 5FU infusion in patients with advanced colon carci-
noma. Capecitabine administered on a metronomic
schedule instead of 5FU infusion should be tested in
patients with advanced neuroendocrine carcinoma, thus
obviating the need for an implantable central venous
access.
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